Study Maps Economic Fallout of NIH Cuts in Georgia

The Science & Community Impacts Mapping Project (SCIMaP) shows how proposed federal funding cuts lead to reduced economic activity and job losses nationwide.

Georgia faces severe economic consequences as the Trump administration plans significant cuts to indirect funding by the National Institutes of Health (NIH). According to the Science & Community Impacts Mapping Project, Georgia stands to lose approximately $327 million in funding and 1,414 jobs, with effects rippling through communities across the state. 

 

Georgia's projected $327 million loss is part of a broader national impact. According to the project's findings, nearly half of all U.S. counties will experience economic losses of at least $250,000, with more than 500 counties losing over $6.25 million in funding. 

 

Ripple Effects on Innovation and Healthcare 

Beyond immediate economic losses, the cuts threaten Georgia's position in biomedical innovation. The state has historically leveraged NIH funding to: 


  • Develop groundbreaking medical treatments
  • Establish biotechnology startups
  • Train the next generation of healthcare professionals and researchers
  • Address critical public health challenges 


The proposed cuts would affect not only our state's major research universities but also regional institutions and the communities they support throughout the state. For communities already facing economic challenges, the loss of research-related economic activity could exacerbate existing problems. 

 

Looking Forward 

The Science & Community Impacts Mapping Project provides a sobering look at what's at stake for Georgia's communities when research funding diminishes, highlighting how federal research investment creates economic value far beyond laboratory walls. 

December 10, 2025
Georgia Life Sciences has joined 43 state and regional life sciences organizations in signing a national Council of State Bioscience Associations (CSBA) letter calling on Congress to take immediate action on three bipartisan policy priorities that are essential to sustaining U.S. leadership in biomedical innovation and supporting patients nationwide. With Congress back in session and several critical programs at risk of expiring, the letter urges congressional leaders to advance the following provisions without delay: 1. Reauthorize the Rare Pediatric Disease Priority Review Voucher (PPRV) Program The PPRV program has been instrumental in incentivizing the development of therapies for children with rare and life-threatening conditions. Its lapse threatens to slow or halt research that families across the country are counting on. 2. Extend the SBIR/STTR Programs The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs provide crucial early-stage capital for emerging biotech and medtech companies—many of them in Georgia. Without reauthorization, hundreds of innovative small businesses face uncertainty, jeopardizing new therapies, diagnostics, and technologies in the pipeline, 3. Advance PBM Transparency Reforms Greater transparency and accountability within pharmacy benefit manager (PBM) practices are needed to ensure that savings reach patients and employers. Reforming PBM operations is essential to strengthening access and affordability across the healthcare system. A Unified Message from the Life Sciences Community The sign-on letter reflects broad, bipartisan alignment across the national life sciences ecosystem: researchers, entrepreneurs, investors, patient advocates, and state associations all share a common message— these programs underpin America’s global competitiveness and are vital to patients who rely on continued scientific progress. Georgia Life Sciences has shared the letter with members of Georgia’s congressional delegation and will continue engaging with policymakers to emphasize the importance of swift action.
December 7, 2025
Georgia Life Sciences is proud to stand with patient advocates, providers, and employers across the state in urging Congress to take meaningful action on pharmacy benefit manager (PBM) reform. We recently signed on to a joint letter to Georgia’s Congressional Delegation stressing the urgent need for transparency, fair practices, and policies that ensure savings flow directly to patients.
December 4, 2025
Georgia Life Sciences’ CEO, Maria Thacker Goethe shares her perspective on the value of Georgia’s research universities in this month’s issue of Georgia Trend. “Georgia research institutions have felt a very significant impact from the federal rollbacks, specifically in NIH and NSF funding. Thacker Goethe’s message about the impact of research cuts is simple: Disruption shatters the foundational trust researchers have in grant continuity….” To read the full article, click here .
MORE POSTS